Erin Wilson
Stock Analyst at Morgan Stanley
(1.81)
# 3,211
Out of 5,182 analysts
23
Total ratings
46.15%
Success rate
0.75%
Average return
Main Sectors:
Stocks Rated by Erin Wilson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RPD Rapid7 | Maintains: Equal-Weight | $28 → $22 | $5.37 | +309.68% | 8 | Sep 2, 2025 | |
| ALGN Align Technology | Maintains: Outperform | $715 → $732 | $170.60 | +329.07% | 3 | Jul 29, 2021 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $352 → $385 | $173.89 | +121.40% | 1 | Jul 20, 2021 | |
| IQV IQVIA Holdings | Maintains: Outperform | $242 → $265 | $173.26 | +52.95% | 1 | Jul 20, 2021 | |
| MEDP Medpace Holdings | Maintains: Outperform | $200 → $205 | $498.34 | -58.86% | 1 | Jul 20, 2021 | |
| ICLR ICON Public Limited Company | Maintains: Outperform | $245 → $250 | $114.19 | +118.93% | 2 | Jul 20, 2021 | |
| ELAN Elanco Animal Health | Upgrades: Outperform | $33 → $38 | $23.08 | +64.64% | 1 | Feb 26, 2021 | |
| FLGT Fulgent Genetics | Downgrades: Underperform | n/a | $16.82 | - | 1 | Jan 8, 2021 | |
| TMO Thermo Fisher Scientific | Initiates: Neutral | $341 | $491.46 | -30.61% | 1 | Jan 22, 2020 | |
| INCR InterCure | Maintains: Outperform | $68 → $54 | $0.76 | +7,005.26% | 4 | Nov 14, 2017 |
Rapid7
Sep 2, 2025
Maintains: Equal-Weight
Price Target: $28 → $22
Current: $5.37
Upside: +309.68%
Align Technology
Jul 29, 2021
Maintains: Outperform
Price Target: $715 → $732
Current: $170.60
Upside: +329.07%
Charles River Laboratories International
Jul 20, 2021
Maintains: Neutral
Price Target: $352 → $385
Current: $173.89
Upside: +121.40%
IQVIA Holdings
Jul 20, 2021
Maintains: Outperform
Price Target: $242 → $265
Current: $173.26
Upside: +52.95%
Medpace Holdings
Jul 20, 2021
Maintains: Outperform
Price Target: $200 → $205
Current: $498.34
Upside: -58.86%
ICON Public Limited Company
Jul 20, 2021
Maintains: Outperform
Price Target: $245 → $250
Current: $114.19
Upside: +118.93%
Elanco Animal Health
Feb 26, 2021
Upgrades: Outperform
Price Target: $33 → $38
Current: $23.08
Upside: +64.64%
Fulgent Genetics
Jan 8, 2021
Downgrades: Underperform
Price Target: n/a
Current: $16.82
Upside: -
Thermo Fisher Scientific
Jan 22, 2020
Initiates: Neutral
Price Target: $341
Current: $491.46
Upside: -30.61%
InterCure
Nov 14, 2017
Maintains: Outperform
Price Target: $68 → $54
Current: $0.76
Upside: +7,005.26%